Why Is HEMAB THERAPEUTICS H (COAG) Stock Up Today?

Hemab Therapeutics Hldgs (COAG) surged 10.24% to $43.55 on Tuesday, driven by positive clinical data and analyst upgrades. The stock opened with an 8.7% gap up and traded as high as $43.67 during the session. The rally followed the company's presentation of clinical and preclinical data for its drug candidate Sutacimig at the ISTH 2026 Congress, which included successful hemostatic outcomes in three patients.

What Happened

[StockTitan] reported that Hemab Therapeutics presented data showing three successful hemostatic outcomes in a 34-patient extension trial of Sutacimig for Glanzmann Thrombasthenia and Factor VII Deficiency. The FDA has endorsed a 0.2 mg/kg weekly dose for Phase 3 trials, which are expected to begin in the second half of 2026. This update was accompanied by a strong AI sentiment score of 73 out of 100.

[benzinga] provided additional context, noting that Jefferies upgraded Hemab to Buy and raised its price target to $47, while Wedbush reiterated its Outperform rating and maintained a $55 price target. These analyst actions suggest growing confidence in the company’s pipeline and therapeutic potential.

What The Data Shows

The stock opened at $42.95 and traded as low as $38.36 before recovering to a high of $43.67. The session volume of 0.2M shares was below average. Institutional activity also supported the move, with Ra Capital Management, L.P. making three separate purchases totaling 10% of the company’s shares over the past month. Insider transactions over the last 90 days include four buys totaling $3.2M and no sells, indicating continued confidence from major stakeholders.

What To Watch

While Hemab Therapeutics has no upcoming earnings date, the market will closely monitor the progress of its Phase 3 trial planning for Sutacimig in 2026. Analyst coverage remains positive, with two firms maintaining elevated price targets. Investors should also watch for further insider activity and any additional clinical updates from the company.